

**Chronic kidney disease: Early identification and management of chronic
disease in adults in primary and secondary care (partial update)**

National Clinical Guideline Centre

6th Guideline Development Group Meeting

Date and Time: 12th April 2013 10:00–16:00

Place: NCGC, 180 Great Portland Street, London

Invited:

Technical team Paul Stevens, Chair (PS)
Caroline Blaine, Research Fellow (CB)
Serena Carville, Senior Research Fellow (& Project Manager)(SC)
Quyên Chu, Senior Project Manager (QC)
Lilian Li, Health Economist (LL)
Jill Parnham, Guideline Lead (JP)

GDG members Paula D'Souza, Renal Nurse
Hugh Gallagher, Nephrologist
Kathryn Griffith, GP
Karen Jenkins, Renal Nurse
Paul Kendrew, Renal Pharmacist
Ed Lamb, Clinical Biochemist
Robert Lewis, Nephrologist
Fiona Loud, Lay Member
Shelagh O'Riordan, Geriatrician
Paul Roderick, Professor of Public Health

Apologies Ben Doak, NICE Guideline Commissioning Manager
Nicholas Palmer, Lay Member

Minutes

- 1. Introductions and apologies.** PS welcomed everyone to the meeting. Apologies were noted from Nicholas and Ben.
- 2. Declarations of Interest.** All GDG members were asked to verbally declare any new declarations of interests since GDG5. New declarations of interests were declared by Paul Stevens, Paul Kendrew, Paula D'Souza, Karen Jenkins and Fiona Loud.

Paul Stevens declared the following interests:

- o Co-applicant for a £2M grant just awarded by the NIHR (non-pharma) for a multicentre study assessing the utility of cystatin C for CKD progression. Non personal pecuniary – action taken –

declare and participate (non healthcare industry related).

- o Invited speaker at a French Society of Nephrology meeting in Lyon; subject 'How to control the CKD workload'. Travel expenses and hotel accommodation sponsored by Hemotech (French dialysis company). Personal pecuniary – action taken – declare and participate (standard reasonable expenses).
- o Speaking at the British Renal Society (BRS); subject 'The BRS in the NICE era'. Travel, registration and accommodation paid by the BRS. Personal pecuniary – action taken – declare and participate (standard reasonable expenses).
- o Speaking at the World Congress of Nephrology (Hong Kong); subject 'KDIGO – clinical practice guidelines for evaluation and management of CKD: research gaps from an international perspective'. Travel, registration and accommodation paid by the International Society of Nephrology. Personal pecuniary – action taken – declare and participate (standard reasonable expenses).

Paul Kendrew declared the following interests:

- o Attended a talk and a dinner sponsored by Takeda at the BTS. [N.B. Dinner was limited to only those who went to the Takeda-sponsored talk]. Personal and specific pecuniary interest – action taken was declare and withdraw from GDG7 May 2013 (Q10: RAAS question).

Paula D'Souza declared the following interests:

- o Gave presentation to HCPs on CKD and its management in primary care, sponsored by Astra Zeneca; petrol expenses received. Personal pecuniary interest – action taken – standard reasonable expenses declare and participate.
- o Will be attending the ERA (Istanbul) 18-21 May 2013; registration, economy flights and standard accommodation funded by Boeringer Ingelheim. Personal pecuniary interest – action taken – standard reasonable expenses declare and participate.

Karen Jenkins declared the following interest:

- o Attending annual ANSA conference; travel, registration and accommodation paid by ANSA. Personal pecuniary – action taken – standard reasonable expenses declare and participate.
- o Chairing a session at British Renal Society (BRS) Conference; subject 'How CKD contributes to cardiovascular risk and improving patient outcomes. Attending the British Renal Society Conference as a member of the BRS council and CKD Strategy Group Chair. Travel, registration and accommodation paid by the BRS. Personal pecuniary – action taken – standard reasonable expenses declare and participate.
- o Co-authored editorial for Journal of Renal Nursing entitled 'Patient self care: are we getting the balance right?'; due to receive personal payment as a Consultant Editor for JRN. Personal pecuniary – action taken– declare and participate (non healthcare industry related).

Fiona Loud declared the following interest:

- o Co-applicant for a £2M grant just awarded by the NIHR (non-pharma) for a multicentre study assessing the utility of cystatin C for CKD progression. Pecuniary (but neither personal nor non-personal (no managerial responsibility for dept)) – action taken – declare and participate.
- o Speaking on Patient Decision Aids at ReMec (Renal Medicine, run by Central Manchester University Hospitals NHS Foundation Trust Hospital) meeting in Warrington; will receive travel expenses and speaker fee. Personal pecuniary non specific – action taken – declare and participate.

- o Speaking at the British Renal Society on 'What I want my care to look like in 2023' and 'Commissioning – patient perspective on involvement to improve our service.' Travel, registration and accommodation paid by the British Renal Society. Personal pecuniary – action taken – standard reasonable expenses declare and participate.
3. **Draft working notes and NICE minutes from GDG5.** The draft working notes from GDG5 were agreed with a few minor corrections and the NICE minutes from GDG5 were signed-off with changes.
 4. **Evidence review: Measurement of kidney function (continued).** The evidence report was presented by CB and the GDG discussed draft recommendations.
 5. **Evidence review: Classification of CKD.** The evidence report was presented by SC and the GDG discussed draft recommendations.
 6. **Health economic Cystatin C cost analysis.** LL presented the updated plan for the economic analysis. The GDG discussed the presentation and content, and agreed some of the inputs.
 7. **Any other business.** An update of the progress of recommendations made to date will be circulated to the GDG. Key time points for key milestones for the guideline will be included as a meeting paper at the next GDG meeting.

Date, time and venue of the next meeting:

17th May 2013, 10:00–16:00, Boardroom, NCGC offices, 180 Great Portland Street